Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06486142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Name: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study — clinical trial record (NCT06486142)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ERIS

StatusRecruiting

PhasePhase 3

SponsorRegion Skane

Started2022-09-21

View on ClinicalTrials.gov ↗

Amendment history

2026-05-11

Study Status, Outcome Measures v1

Secondary endpointsdetails revised at 2 of 7 entries

2024-06-26

Original filing

Region Skane

146 trials monitored

See 5 trials at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.

Trial Details

NCT Number	NCT06486142
Lead Sponsor	Region Skane Collaborators: Swedish Lung Cancer Study Group
Conditions	Non-Small Cell Lung Cancer
Enrollment	200 participants
Start Date	2022-09-21
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-14